Source link : https://www.newshealth.biz/health-news/vedolizumab-edges-out-infliximab-for-ulcerative-colitis-in-real-world-study/
ORLANDO — Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor antagonist vedolizumab slightly edged out the tumor necrosis factor (TNF) blocker in some areas, according to a real-world dataset. At 52 weeks, there was no significant difference in […]
Author : News Health
Publish date : 2024-12-19 15:14:04
Copyright for syndicated content belongs to the linked Source.